AbbVie News Center - News
Abb Vie Mediaroom. Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A....
Read Abbvie.mediaroom.com news digest here: view the latest Abb Vie Mediaroom articles and content updates right away or get to their most visited pages. Abbvie.mediaroom.com is not yet rated by Alexa and its traffic estimate is unavailable. It seems that Abb Vie Mediaroom content is notably popular in USA. We haven’t detected security issues or inappropriate content on Abbvie.mediaroom.com and thus you can safely use it. Abbvie.mediaroom.com is hosted with CloudFlare, Inc. (United States) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
N/A
Visitors daily -
N/A
Pageviews daily -
5
Google PR -
N/A
Alexa rank
Best pages on Abbvie.mediaroom.com
-
News Center | AbbVie News Center
AbbVie Inc. Newsroom - the official site for press releases, photos, video, audio, pr contact information, presskits and more.
-
AbbVie (NYSE: ABBV) today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company,...
Abbvie.mediaroom.com news digest
-
4 months
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strength...
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage...
-
4 months
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artifi...
Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation...
-
4 months
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mir...
Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant...
-
4 months
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluati...
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in...
Domain history
| Web host: | CloudFlare, Inc. |
| Registrar: | CSC Corporate Domains, Inc. |
| Registrant: | Not Disclosed Not Disclosed (Not Disclosed) |
| Updated: | January 29, 2024 |
| Expires: | February 02, 2025 |
| Created: | May 05, 2001 |
Whois record
Safety scores
Trustworthiness
GoodChild safety
N/A
